In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target of $11.00. The company’s shares closed yesterday at $3.27.
According to TipRanks, Burns is an analyst with an average return of -22.4% and a 21.30% success rate. Burns covers the Healthcare sector, focusing on stocks such as Kinnate Biopharma, Portage Biotech Inc, and Springworks Therapeutics.
Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $13.67, implying a 318.04% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $18.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $7.90 and a one-year low of $1.96. Currently, Autolus Therapeutics has an average volume of 152.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Read More on AUTL:
- Moderna Rises on Major Developments
- Moderna exercises option to license proprietary targeting technology from Autolus
- Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
- Autolus Therapeutics collaborates with Bristol-Myers for use of safety switch
